Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSC072
MIFTS: 45

Muscle Cancer

Categories: Cancer diseases, Muscle diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Muscle Cancer

About this section

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 54 15 17
Myosarcoma 12 54 43 71
Malignant Neoplasm of Muscle 12 71
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 71
Muscle Neoplasms 43

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4045
NCIt 49 C4883
SNOMED-CT 67 20667008 363495004
ICD10 32 C49
UMLS 71 C0027095 C0282606 C0684743
Sources

Summaries for Muscle Cancer

About this section
Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to skeletal muscle neoplasm and skeletal muscle cancer, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and C-MYB transcription factor network. The drugs Doxycycline and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include muscle, liver and uterus, and related phenotypes are integument and muscle

Wikipedia : 74 A soft-tissue sarcoma (STS) is a form of sarcoma that develops in connective tissue, though the term is... more...

Sources

Related Diseases for Muscle Cancer

About this section

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 skeletal muscle neoplasm 34.5 RHD MYOG MYOD1
2 skeletal muscle cancer 33.6 TFE3 SERPINA3 RHD PAX7 PAX3 MYOG
3 myoma 33.5 KIT CD34 CALD1
4 uterus leiomyosarcoma 32.5 MYOG KIT CALD1
5 rhabdomyosarcoma 32.5 PAX7 PAX3 MYOG MYOD1 KIT FOXO1
6 leiomyosarcoma 32.3 SERPINA3 MYOG KIT DES
7 spindle cell sarcoma 31.6 SERPINA3 MYOG DES CD34
8 prostate rhabdomyosarcoma 31.2 MYOG MYOD1
9 botryoid rhabdomyosarcoma 31.2 PAX3 MYOG MYOD1 DES
10 sarcoma 31.1 TFE3 SERPINA3 MYOG MYOD1 KIT FOXO1
11 infantile myofibromatosis 31.1 DES CD34 CALD1
12 prostate embryonal rhabdomyosarcoma 31.1 MYOG MYOD1 KIT CALD1
13 hemangiopericytoma, malignant 30.9 SERPINA3 MYOG KIT DES CD34 CALD1
14 cutaneous leiomyosarcoma 30.9 DES CALD1
15 smooth muscle tumor 30.9 SERPINA3 KIT DES CD34 CALD1
16 intravenous leiomyomatosis 30.8 DES CD34 CALD1
17 angiomyoma 30.5 CD34 CALD1
18 angiomyolipoma 30.5 TFE3 KIT DES
19 liver leiomyoma 30.5 KIT CD34
20 endometrial stromal sarcoma 30.4 KIT EWSR1 DES CALD1
21 embryonal rhabdomyosarcoma 30.4 PAX7 PAX3 MYOG MYOD1 FOXO1 EWSR1
22 cellular leiomyoma 30.3 DES CALD1
23 vulvar leiomyoma 30.3 CD34 CALD1
24 myopathy 30.2 SERPINA3 PAX7 MYOG MYOD1 LIPE FBXO32
25 mesenchymal cell neoplasm 30.1 TFE3 SERPINA3 MYOG MIR199A1 KIT EWSR1
26 mixed endometrial stromal and smooth muscle tumor 11.2
27 striated muscle rhabdoid tumor 10.9
28 bladder sarcoma 10.8 SERPINA3 MYOG
29 central nervous system rhabdomyosarcoma 10.8 PAX3 FOXO1
30 orbit rhabdomyosarcoma 10.8 PAX3 MYOG
31 breast rhabdomyosarcoma 10.7 PAX3 MYOG MYOD1
32 undifferentiated embryonal sarcoma of the liver 10.7 SERPINA3 MYOG MYOD1
33 inflammatory leiomyosarcoma 10.7 PAX7 MYOG DES
34 gallbladder sarcoma 10.7 MYOG MYOD1 DES
35 ovarian fibrothecoma 10.7 KIT DES
36 malignant triton tumor 10.7 MYOG MYOD1 DES
37 fibroma 10.7 SERPINA3 DES CD34
38 lung combined type small cell carcinoma 10.7 MYOG CALD1
39 clear cell basal cell carcinoma 10.7 PAX7 PAX3 MYOG
40 extraskeletal chondroma 10.7 SERPINA3 EWSR1
41 spinal cord sarcoma 10.7 KIT CD34
42 urethra leiomyoma 10.7 KIT CALD1
43 pineal region teratoma 10.7 MYOG MYOD1 KIT
44 congenital epulis 10.7 SERPINA3 DES
45 liver sarcoma 10.7 SERPINA3 MYOG CD34
46 gallbladder leiomyoma 10.7 KIT CD34
47 epulis 10.7 SERPINA3 DES
48 intravascular angioleiomyoma 10.7 CD34 CALD1
49 horner's syndrome 10.7 MYOG MYOD1 DES
50 breast myofibroblastoma 10.7 CD34 CALD1

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer
Sources

Symptoms & Phenotypes for Muscle Cancer

About this section

UMLS symptoms related to Muscle Cancer:


muscle weakness, myoclonus, myalgia, torticollis, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Muscle Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.61 CD34 FOXO1 KIT LIPE MYOG PAX3
2 muscle MP:0005369 9.28 DES FBXO32 FOXO1 KIT LIPE MYOD1
Sources

Drugs & Therapeutics for Muscle Cancer

About this section

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
2 Anti-Infective Agents Phase 4
3 Anti-Bacterial Agents Phase 4
4 Antiparasitic Agents Phase 4
5 Antiprotozoal Agents Phase 4
6 Antimalarials Phase 4
7
Pembrolizumab Approved Phase 3 1374853-91-4
8
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
9
Gemcitabine Approved Phase 3 95058-81-4 60750
10 Immunologic Factors Phase 3
11 Immunosuppressive Agents Phase 3
12 Antimetabolites Phase 3
13 Antineoplastic Agents, Immunological Phase 3
14 Antiviral Agents Phase 3
15
Melphalan Approved Phase 2 148-82-3 460612 4053
16
Mesna Approved, Investigational Phase 2 3375-50-6 598
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Ifosfamide Approved Phase 2 3778-73-2 3690
19 Alkylating Agents Phase 2
20
Liposomal doxorubicin Phase 2 31703
21
Isophosphamide mustard Phase 2 0
22 Vaccines Phase 1, Phase 2
23
Fluorouracil Approved Phase 1 51-21-8 3385
24
Parathyroid hormone Approved, Investigational Phase 1 9002-64-6
25
Belinostat Approved, Investigational Phase 1 866323-14-0
26 Histone Deacetylase Inhibitors Phase 1
27 Androgens Phase 1
28 Analgesics, Non-Narcotic Phase 1
29 Analgesics Phase 1
30 Cola Phase 1
31 Interleukin-2 Phase 1
32 Liver Extracts Phase 1
33 Antibiotics, Antitubercular Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis. Completed NCT00989742 Phase 4 Doxycycline;Placebo
2 A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-905) Recruiting NCT03924895 Phase 3 Pembrolizumab
3 A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866) Recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
4 Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity Completed NCT00019968 Phase 2 melphalan;tumor necrosis factor
5 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Active, not recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
6 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Enrolling by invitation NCT01883518 Phase 1, Phase 2
7 A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
8 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
9 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
10 Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study Unknown status NCT02380651

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Sources

Genetic Tests for Muscle Cancer

About this section
Sources

Anatomical Context for Muscle Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

19
Muscle

MalaCards organs/tissues related to Muscle Cancer:

40
Liver, Uterus, Testis, Skeletal Muscle, Lung, Heart, Colon
Sources

Publications for Muscle Cancer

About this section

Articles related to Muscle Cancer:

(show top 50) (show all 132)
# Title Authors PMID Year
1
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 54 61
16140913 2005
2
Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. 54 61
11473460 2001
3
Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation. 61 54
9796719 1998
4
Opposing effects of 25-hydroxy- and 1α,25-dihydroxy-vitamin D3 on pro-cachectic cytokine-and cancer conditioned medium-induced atrophy in C2C12 myotubes. 61
30834670 2019
5
Diagnostic immunohistochemistry for canine cutaneous round cell tumours - retrospective analysis of 60 cases. 61
31553052 2019
6
Effect of Ninjin'yoeito on the Loss of Skeletal Muscle Function in Cancer-Bearing Mice. 61
30555329 2018
7
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. 61
28250653 2017
8
Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. 61
26071135 2015
9
Application experience of intraoperative neuromonitoring in thyroidectomy. 61
26885214 2015
10
Differential cytotoxic properties of Helleborus niger L. on tumour and immunocompetent cells. 61
25446603 2015
11
YAPping about differentiation therapy in muscle cancer. 61
25117705 2014
12
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. 61
23665679 2014
13
The not-so-skinny on muscle cancer. 61
23079652 2012
14
Mouse models of sarcomas: critical tools in our understanding of the pathobiology. 61
23036318 2012
15
AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. 61
22333587 2012
16
Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. 61
21423212 2011
17
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. 61
21493592 2011
18
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. 61
21447712 2011
19
Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs. 61
20716815 2010
20
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. 61
20193046 2010
21
A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. 61
19491398 2009
22
Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. 61
19339268 2009
23
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. 61
19299559 2009
24
Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. 61
18923454 2009
25
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. 61
18679424 2008
26
[Non-epithelial tumors of the large intestine]. 61
19172837 2008
27
A new model for muscle cancer. 61
17585343 2007
28
Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. 61
16964289 2007
29
The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. 61
16488997 2006
30
Malignancy-induced autoimmunity to MUC1: initial antibody characterization. 61
16316451 2005
31
Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. 61
15981282 2005
32
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. 61
15489287 2004
33
New chromanone acids with antibacterial activity from Calophyllum brasiliense. 61
15104480 2004
34
Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. 61
14968209 2004
35
Synergistic effects of adenosine A1 and P2Y receptor stimulation on calcium mobilization and PKC translocation in DDT1 MF-2 cells. 61
12825834 2003
36
In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. 61
12447687 2002
37
Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. 61
12151977 2002
38
Successful resection of a re-occurred pulmonary myosarcoma in a patient with turner syndrome mosaic. 61
18521351 2002
39
Modification of hemostatic status improves antitumor efficiency of photodynamic therapy. 61
11427917 2001
40
[Primitive leiomyosarcoma of the right atrium presenting with a pulmonary embolism]. 61
10830098 2000
41
Aggressive congenital fibromatosis of the small intestine in the newborn. Report of a case and review of the literature. 61
10661858 1999
42
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. 61
9615866 1998
43
[Bladder leiomyosarcoma. Report of a new case]. 61
9065095 1996
44
Retrorectal tumors complicating pregnancy. Report of two cases. 61
8831537 1996
45
[Antithrombogenic activity of blood vessel walls in the pathogenesis of metastasis in tumor-bearing animals]. 61
8966053 1996
46
Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity. 61
7737913 1995
47
Radioimmunoscintigraphy using [111In]antimyosin Fab fragments for the diagnosis and follow-up of rhabdomyosarcoma. 61
8297646 1993
48
Myofibromatosis-like hemangiopericytoma metastasizing as differentiated vascular smooth-muscle and myosarcoma. Myopericytes as a subset of "myofibroblasts". 61
1463097 1992
49
Angiomatoid "malignant fibrous histiocytoma": an immunohistochemical study indicative of myoid differentiation. 61
1650754 1991
50
Ultrasound appearance of extratesticular myosarcoma. 61
1847943 1991
Sources

Variations for Muscle Cancer

About this section
Sources

Expression for Muscle Cancer

About this section
Search GEO for disease gene expression data for Muscle Cancer.
Sources

Pathways for Muscle Cancer

About this section

Pathways related to Muscle Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transcriptional misregulation in cancer 36
11.64 TFE3 PAX7 PAX3 FOXO1 EWSR1
2
C-MYB transcription factor network 1
11.39 MYOD1 KIT CD34
3
Regulation of nuclear SMAD2/3 signaling 1
11.32 TFE3 MYOD1 FOXO1
4
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.15 PAX7 PAX3 MYOG MYOD1 KIT DES
5
Cell Differentiation - Index 1
10.91 MYOD1 MIR9-1 MIR199A1
Sources

GO Terms for Muscle Cancer

About this section

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.1 TFE3 PAX7 PAX3 MYOG MYOD1 FOXO1

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.83 MIR9-1 MIR675 MIR378A MIR199A1 MIR183
2 negative regulation of osteoblast proliferation GO:0033689 9.4 MIR9-1 MIR675
3 myotube differentiation GO:0014902 9.37 MYOG MYOD1
4 skeletal muscle tissue development GO:0007519 9.33 PAX7 MYOG MYOD1
5 response to denervation involved in regulation of muscle adaptation GO:0014894 9.32 MYOG FBXO32
6 positive regulation of skeletal muscle fiber development GO:0048743 9.26 MYOG MYOD1
7 muscle cell fate commitment GO:0042693 8.96 MYOG MYOD1
8 muscle organ development GO:0007517 8.92 PAX7 PAX3 MYOG MYOD1

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.63 TFE3 PAX7 PAX3 MYOG MYOD1 FOXO1
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.43 TFE3 PAX7 PAX3 MYOG MYOD1 FOXO1
3 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR9-1 MIR675 MIR378A MIR199A1 MIR183
Sources

Sources for Muscle Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....